Background. Mitomycin C and etoposide have both demonstrated activity against gastric carcinoma. Etoposide is a topoisomerase II inhibitor with evidence for phase-specific and schedule-dependent activity.
Introduction
Gastric cancer is predominantly a disease of middle and old age with most people presenting over the age of 50 years. Frequently, it is advanced at the time of diagnosis and patients are of poor performance status. Despite advances in chemotherapy, few patients survive more than a year. In the 1970s, single agent chemotherapeutic drugs such as 5-fluorouracil (5-FU), doxorubicin, mitomycin C, cisplatin and etoposide produced response rates of between 5% and 25% [1] . Subsequent development of intensive combination chemotherapy schedules has increased the number of responses but led to only marginal improvements in disease-free and overall survival [2] .
Etoposide, administered as short intravenous infusions, has shown activity both alone and in combination in the treatment of gastric cancer [3, 4] . In vitro studies suggest that its main mechanism of action is as a topoisomerase II inhibitor, with effectiveness being phasespecific and therefore schedule-dependent [5] . There is good evidence from other tumour types that the schedule of administration is crucial in vivo and that protracted intravenous or oral administration significantly improves response rates [6] . Prolonged oral etoposide in combination with 5-FU and leucovorin has previously been reported to be well tolerated, producing a response rate of 28%, in 25 patients with advanced gastric cancer [3] .
This phase II study was designed to assess the toxicity and efficacy of a protracted oral schedule of etoposide in combination with bolus injections of mitomycin C.
Patients and methods
Between July 1993 and April 1996, 28 consecutive patients with advanced gastric or lower oesophageal adenocarcinoma were entered into the study (Table 1) . Eligibility criteria included histological proof of diagnosis, age over 18 years, verbal informed consent, life expectancy > 3 months, and measurable or evaluable disease on CT scan. prophylaxis consisted of dexamethasone 8 mg i v. and metoclopramide 10 mg i.v. prior to the mitoraycin C followed by metoclopramide 10 mg q.d.s./p.r.n whilst taking etoposide. Treatment was delayed for one week in patients with an absolute neutrophil count < 1.5 x 10 9 /l or platelet count =$ 100 x 10 9 /l. In those patients whose treatment was delayed, the duration of administration of etoposide was reduced from 14 days to 10 days and then to seven days if further delay was experienced. Toxicity was graded according to the WHO criteria and disease response was evaluated by CTscan after every two courses and at the completion of treatment.
Results

Toxicity
A total of 107 courses of chemotherapy were administered with a median number of four treatments per patient. Eight patients received the maximum of six courses and two discontinued treatment after only one course (one with symptomatic disease progression and one who died following oesophageal perforation at upper GI endoscopy). There were no grade IV toxicities and no episodes of neutropenic sepsis (Table 2) . One patient developed infection requiring i.v. antibiotics but was not neutropenic during hospitalisation. Nausea and vomiting was generally well controlled with metoclopramide and dexamethasone. Fatigue was seen in 15 of 27 patients of whom two experienced grade III toxicity. The majority of patients who received more than one cycle of chemotherapy developed moderate or severe alopecia.
Response
Twenty-six patients were considered evaluable for response of whom 12 had measurable bidimensional disease and 14 had evaluable unidimensional disease on CT scan. The CT scans were independently reviewed by a radiologist upon completion of the study.
One complete response and three partial responses were seen with an overall response rate of 15% (95% CI 4%-35%). Two were in patients with primary gastric carcinoma and two with oesophageal carcinoma. The complete response has persisted 24 months after treatment. Eight patients had stable disease of at least three months duration and 14 progressive disease. Of the two patients previously treated with 5-FU and folinic acid, one completed six courses of treatment with stable disease and the other had progressive disease after four courses. The median survival for all patients entered into the study was six months. For those with stable disease or documented response, the median survival was 9.5 months.
Discussion
The combination of mitomycin C and oral etoposide used in this study has shown modest activity with mini- mal toxicity. The objective response rate of 15% is comparable to that previously reported for single-agent mitomycin C and lower than for more intensive combination schedules. The small number of observed responses may be partly attributable to the large proportion of patients with primary oesophageal or gastro-oesophageal tumours.
The activity of etoposide is thought to be highly dependent upon the schedule of administration and the duration for which plasma levels are maintained above a minimum threshold (1 ug ml" 1 in the case of small-cell lung cancer) [6] . When using oral preparations there is wide inter and intra individual variation in absorption and bioavailability. A small study in eight patients with gastric cancer has suggested that pharmacokinetics are not significantly altered in the presence of gastric cancer or gastrectomy [7] . A schedule of 50 mg capsules twice daily, has previously been shown to produce plasma etoposide levels > 1 ug ml" 1 for a median of 14 hours per 24 hours [8] . No pharmacokinetic monitoring was performed to confirm that this minimum concentration was reached in this patient group.
The use of protracted etoposide containing schedules may hold some promise either alone or in combination in gastric cancer. Further work should assess whether protracted single agent etoposide is active by using prolonged intravenous infusions of etoposide or of the more stable prodrug etoposide phosphate. Pharmacokinetic monitoring would allow for accurate adjustment in the dose administered and thus overcome the unpredictability of the oral route and the variability in bioavailability between patients. This would inevitably be a more intensive treatment but could still be easily administered with minimal toxicity.
The treatment of advanced gastric cancer remains palliative with few tumour responses translating into prolonged survival. The overall median survival in this study was six months which is equivalent to other studies. Any chemotherapy schedule used in this context needs to be easily administered, preferably in the outpatient clinic, and produce minimal toxicity in what is frequently an elderly population. This must be balanced against clinical efficacy.
